{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:29:42Z","timestamp":1791286182348,"version":"4.1.0"},"reference-count":168,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"CSL Vifor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Vitamin D is a pre-hormone essential for maintaining mineral homeostasis and also plays significant roles in bone, cardiovascular and renal health. Vitamin D deficiency is prevalent in the general population, and even more so in chronic kidney disease (CKD) patients, in which it contributes to the development and progression of mineral and bone disorder. The landscape of vitamin D treatment has evolved, with several analogues now available, each possessing distinct pharmacokinetic and pharmacodynamic properties, efficacies and safety profiles. This diversity allows for tailored, personalized approaches to treatment in CKD patients. This review aims to provide a comprehensive overview of vitamin D, including its natural sources and metabolism, and examines the main available pharmacological vitamin D products. Particular emphasis is placed on their application in CKD management, highlighting how these compounds can be strategically used to address both vitamin D deficiency and secondary hyperparathyroidism, while also acknowledging the ongoing debate about their impact on bone health and other clinical outcomes.<\/jats:p>","DOI":"10.1093\/ckj\/sfae417","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:03:51Z","timestamp":1741824231000},"page":"i61-i96","source":"Crossref","is-referenced-by-count":8,"title":["Vitamin D: are all compounds equal?"],"prefix":"10.1093","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2853-1332","authenticated-orcid":false,"given":"Lorenza","family":"Magagnoli","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Cassia","sequence":"additional","affiliation":[{"name":"Nephrology Unit, Spedali Civili di Brescia Hospital, ASST Spedali Civili di Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Galassi","sequence":"additional","affiliation":[{"name":"Renal and Dialysis Unit, ASST Rhodense, Garbagnate , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ciceri","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Nephrology, Department of Health Sciences, University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Mass\u00f3","sequence":"additional","affiliation":[{"name":"Nephrology Department, University Hospital Germans Trias I Pujol, REMAR-IGTP Group, RICORS 2040 Network , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"Gelpi","sequence":"additional","affiliation":[{"name":"Nephrology Department, University Hospital Germans Trias I Pujol, REMAR-IGTP Group, RICORS 2040 Network , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bover","sequence":"additional","affiliation":[{"name":"Nephrology Department, University Hospital Germans Trias I Pujol, REMAR-IGTP Group, RICORS 2040 Network , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8494-6252","authenticated-orcid":false,"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of Milan , Milan ,","place":["Italy"]},{"name":"Renal Division, ASST Santi Paolo e Carlo , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"2025031300034024900_bib1","doi-asserted-by":"publisher","first-page":"e210594","DOI":"10.1530\/EC-21-0594","article-title":"100 years of vitamin D: historical aspects of vitamin D","volume":"11","author":"Jones","year":"2022","journal-title":"Endocr Connect"},{"key":"2025031300034024900_bib2","doi-asserted-by":"publisher","first-page":"491S","DOI":"10.1093\/ajcn\/88.2.491S","article-title":"From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health","volume":"88","author":"Norman","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"2025031300034024900_bib3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/039139880903200205","article-title":"Vitamin D: physiology and pathophysiology","volume":"32","author":"Gallieni","year":"2009","journal-title":"Int J Artif Organs"},{"key":"2025031300034024900_bib4","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1210\/me.2006-0031","article-title":"The human transient receptor potential vanilloid type 6 distal promoter contains multiple vitamin D receptor binding sites that mediate activation by 1,25-dihydroxyvitamin D3 in intestinal cells","volume":"20","author":"Meyer","year":"2006","journal-title":"Mol Endocrinol"},{"key":"2025031300034024900_bib5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/jcb.10567","article-title":"Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter","volume":"89","author":"Kitazawa","year":"2003","journal-title":"J Cell Biochem"},{"key":"2025031300034024900_bib6","doi-asserted-by":"publisher","first-page":"10901","DOI":"10.1074\/jbc.273.18.10901","article-title":"A negative vitamin D response DNA element in the human parathyroid hormone-related peptide gene binds to vitamin D receptor along with Ku antigen to mediate negative gene regulation by vitamin D","volume":"273","author":"Nishishita","year":"1998","journal-title":"J Biol Chem"},{"key":"2025031300034024900_bib7","doi-asserted-by":"publisher","first-page":"30337","DOI":"10.1074\/jbc.M201804200","article-title":"Human calcium-sensing receptor gene\u2014vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D","volume":"277","author":"Canaff","year":"2002","journal-title":"J Biol Chem"},{"key":"2025031300034024900_bib8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1210\/er.2004-0002","article-title":"Noncalcemic actions of vitamin D receptor ligands","volume":"26","author":"Nagpal","year":"2005","journal-title":"Endocr Rev"},{"key":"2025031300034024900_bib9","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nrcardio.2016.73","article-title":"Vitamin D and cardiovascular disease prevention","volume":"13","author":"Pilz","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2025031300034024900_bib10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1172\/JCI0215219","article-title":"1,25-dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system","volume":"110","author":"Li","year":"2002","journal-title":"J Clin Invest"},{"key":"2025031300034024900_bib11","doi-asserted-by":"publisher","first-page":"868961","DOI":"10.1155\/2015\/868961","article-title":"Prevalence and prognostic implications of vitamin D deficiency in chronic kidney disease","volume":"2015","author":"Obi","year":"2015","journal-title":"Dis Markers"},{"key":"2025031300034024900_bib12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/kisup.2011.28","article-title":"Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation","volume":"1","author":"Bover","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"2025031300034024900_bib13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"2025031300034024900_bib14","doi-asserted-by":"publisher","first-page":"sfae188","DOI":"10.1093\/ckj\/sfae188","article-title":"Ethnic and seasonal variations in FGF-23 and markers of chronic kidney disease-mineral and bone disorder","volume":"17","author":"Taskapan","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025031300034024900_bib15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1136\/gut.21.4.287","article-title":"Comparative absorption of vitamin D3 and 25-hydroxyvitamin D3 in intestinal disease","volume":"21","author":"Davies","year":"1980","journal-title":"Gut"},{"key":"2025031300034024900_bib16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.annepidem.2007.12.001","article-title":"Vitamin D status: measurement, interpretation, and clinical application","volume":"19","author":"Holick","year":"2009","journal-title":"Ann Epidemiol"},{"key":"2025031300034024900_bib17","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.5740\/jaoacint.17-0196","article-title":"The Vitamin D Standardization Program (VDSP) Manual for Retrospective Laboratory Standardization of Serum 25-Hydroxyvitamin D Data","volume":"100","author":"Durazo-Arvizu","year":"2017","journal-title":"J AOAC Int"},{"key":"2025031300034024900_bib18","doi-asserted-by":"publisher","first-page":"F8","DOI":"10.1152\/ajprenal.00336.2004","article-title":"Vitamin D","volume":"289","author":"Dusso","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025031300034024900_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.chembiol.2013.12.016","article-title":"Vitamin D metabolism, mechanism of action, and clinical applications","volume":"21","author":"Bikle","year":"2014","journal-title":"Chem Biol"},{"key":"2025031300034024900_bib20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1053\/j.ajkd.2024.03.025","article-title":"Vitamin D metabolites before and after kidney transplantation in patients who are anephric","volume":"84","author":"J\u00f8rgensen","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2025031300034024900_bib21","doi-asserted-by":"publisher","first-page":"F203","DOI":"10.1152\/ajprenal.1996.271.1.F203","article-title":"Expression of the renal 25-hydroxyvitamin D-24-hydroxylase gene: regulation by dietary phosphate","volume":"271","author":"Wu","year":"1996","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025031300034024900_bib22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-4781(95)00060-T","article-title":"Cloning of the human 1-\u03b1,25-dihydroxyvitamin-D-3 24-hydroxylase gene promoter and identification of 2 vitamin-D-responsive elements","volume":"1263","author":"Chen","year":"1995","journal-title":"Biochim Biophys Acta"},{"key":"2025031300034024900_bib23","doi-asserted-by":"publisher","first-page":"582S","DOI":"10.1093\/ajcn\/88.2.582S","article-title":"Pharmacokinetics of vitamin D toxicity","volume":"88","author":"Jones","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"2025031300034024900_bib24","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3389\/fendo.2019.00910","article-title":"Vitamin D binding protein: a historic overview","volume":"10","author":"Bouillon","year":"2020","journal-title":"Front Endocrino (Lausanne)"},{"key":"2025031300034024900_bib25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jsbmb.2013.09.012","article-title":"Vitamin D and DBP: the free hormone hypothesis revisited","volume":"144","author":"Chun","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2025031300034024900_bib26","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa1306357","article-title":"Vitamin D-binding protein and vitamin D status of black Americans and white Americans","volume":"369","author":"Powe","year":"2013","journal-title":"N Engl J Med"},{"key":"2025031300034024900_bib27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1373\/clinchem.2011.176545","article-title":"Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitamin D binding protein concentration","volume":"58","author":"Heijboer","year":"2012","journal-title":"Clin Chem"},{"key":"2025031300034024900_bib28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/clinchem\/hvaa238","article-title":"The vitamin D metabolite ratio is independent of vitamin D binding protein concentration","volume":"67","author":"Ginsberg","year":"2021","journal-title":"Clin Chem"},{"key":"2025031300034024900_bib29","doi-asserted-by":"publisher","first-page":"15897","DOI":"10.1074\/jbc.M311473200","article-title":"C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1\u03b1 or C-24 hydroxylation","volume":"279","author":"Kamao","year":"2004","journal-title":"J Biol Chem"},{"key":"2025031300034024900_bib30","doi-asserted-by":"publisher","first-page":"122350","DOI":"10.1016\/j.jchromb.2020.122350","article-title":"Measurement of plasma 25-hydroxyvitamin D2, 25-hydroxyvitamin D3 and 3-epi-25-hydroxyvitamin D3 in population of patients with cardiovascular disease by UPLC-MS\/MS method","volume":"1159","author":"Abouzid","year":"2020","journal-title":"J Chromatogr B"},{"key":"2025031300034024900_bib31","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2025031300034024900_bib32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1017\/S0007114513001840","article-title":"A systematic review of vitamin D status in populations worldwide","volume":"111","author":"Hilger","year":"2014","journal-title":"Br J Nutr"},{"key":"2025031300034024900_bib33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1159\/000081023","article-title":"Vitamin D insufficiency and deficiency in chronic kidney disease: a single center observational study","volume":"24","author":"Gonz\u00e1lez","year":"2004","journal-title":"Am J Nephrol"},{"key":"2025031300034024900_bib34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.5144\/0256-4947.2012.473","article-title":"Vitamin D insufficiency and deficiency in children with chronic kidney disease","volume":"32","author":"Kari","year":"2012","journal-title":"Ann Saudi Med"},{"key":"2025031300034024900_bib35","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40620-024-02055-x","article-title":"Native vitamin D in CKD and renal transplantation: meaning and rationale for its supplementation","volume":"37","author":"Alfieri","year":"2024","journal-title":"J Nephrol"},{"key":"2025031300034024900_bib36","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/ki.1988.190","article-title":"Extra-renal production of calcitriol in chronic renal-failure","volume":"34","author":"Dusso","year":"1988","journal-title":"Kidney Int"},{"key":"2025031300034024900_bib37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1159\/000345146","article-title":"Uremia suppresses immune signal-induced CYP27B1 expression in human monocytes","volume":"36","author":"Viaene","year":"2012","journal-title":"Am J Nephrol"},{"key":"2025031300034024900_bib38","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1172\/JCI116720","article-title":"Decreased 1,25-dihydroxyvitamin-D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients","volume":"92","author":"Fukuda","year":"1993","journal-title":"J Clin Invest"},{"key":"2025031300034024900_bib39","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jsbmb.2004.03.061","article-title":"1,25-dihydroxyvitamin D downregulation of TGF\u03b1\/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure","volume":"89\u201390","author":"Dusso","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2025031300034024900_bib40","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1111\/j.1523-1755.2005.00603.x","article-title":"25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy","volume":"68","author":"Coen","year":"2005","journal-title":"Kidney Int"},{"key":"2025031300034024900_bib41","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3390\/nu13030809","article-title":"Vitamin K and D supplementation and bone health in chronic kidney disease-apart or together?","volume":"13","author":"Zieminska","year":"2021","journal-title":"Nutrients"},{"key":"2025031300034024900_bib42","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1210\/clinem\/dgae290","article-title":"Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline","volume":"109","author":"Demay","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2025031300034024900_bib43","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1210\/jc.2004-0360","article-title":"Vitamin D2 is much less effective than vitamin D3 in humans","volume":"89","author":"Armas","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2025031300034024900_bib44","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00198-018-4520-y","article-title":"Is calcifediol better than cholecalciferol for vitamin D supplementation","volume":"29","author":"Quesada-Gomez","year":"2018","journal-title":"Osteoporos Int"},{"key":"2025031300034024900_bib45","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00394-023-03103-1","article-title":"Calcifediol: a review of its pharmacological characteristics and clinical use in correcting vitamin D deficiency","volume":"62","author":"Jodar","year":"2023","journal-title":"Eur J Nutr"},{"key":"2025031300034024900_bib46","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/ajcn\/46.6.1011","article-title":"Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in chronic cholestatic liver disease","volume":"46","author":"Sitrin","year":"1987","journal-title":"Am J Clin Nutr"},{"key":"2025031300034024900_bib47","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","article-title":"The 25(OH)D level needed to maintain a favorable bisphosphonate response is \u226533\u00a0ng\/ml","volume":"23","author":"Carmel","year":"2012","journal-title":"Osteoporos Int"},{"key":"2025031300034024900_bib48","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jsbmb.2009.11.011","article-title":"25-hydroxyvitamin D3 is an agonistic vitamin D receptor ligand","volume":"118","author":"Lou","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2025031300034024900_bib49","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/14740338.2021.1931117","article-title":"Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency","volume":"20","author":"Galassi","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"2025031300034024900_bib50","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40620-021-01152-5","article-title":"Extended-release calcifediol in stage 3\u20134 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D","volume":"35","author":"Cozzolino","year":"2022","journal-title":"J Nephrol"},{"key":"2025031300034024900_bib51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jsbmb.2014.11.022","article-title":"Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation","volume":"148","author":"Petkovich","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2025031300034024900_bib52","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/ndt\/gfac236","article-title":"Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s","volume":"38","author":"Ketteler","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025031300034024900_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nefroe.2023.03.003","article-title":"Recommendations of the Spanish Society of Nephrology for the management of mineral and bone metabolism disorders in patients with chronic kidney disease: 2021 (SEN-MM)","volume":"43","author":"Torregrosa","year":"2023","journal-title":"Nefrolog\u00eda (Engl Ed)"},{"key":"2025031300034024900_bib54","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1\u03b1-hydroxyvitamin D2) therapy for secondary hyperparathyroidism","volume":"36","author":"Fraz\u00e3o","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"2025031300034024900_bib55","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1345\/aph.1G523","article-title":"Doxercalciferol treatment of secondary hyperparathyroidism","volume":"40","author":"Dennis","year":"2006","journal-title":"Ann Pharmacother"},{"key":"2025031300034024900_bib56","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5603\/EP.2013.0012","article-title":"Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe\u2014recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency","volume":"64","author":"P\u0142udowski","year":"2013","journal-title":"Endokrynol Pol"},{"key":"2025031300034024900_bib57","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/nu14071483","article-title":"Clinical practice in the prevention, diagnosis and treatment of vitamin D deficiency: a Central and Eastern European expert consensus statement","volume":"14","author":"Pludowski","year":"2022","journal-title":"Nutrients"},{"key":"2025031300034024900_bib58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4158\/EP.14.1.10","article-title":"Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study","volume":"14","author":"Chandra","year":"2008","journal-title":"Endocr Pract"},{"key":"2025031300034024900_bib59","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000157177","article-title":"Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease","volume":"31","author":"Oksa","year":"2008","journal-title":"Kidney Blood Press Res"},{"key":"2025031300034024900_bib60","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2215\/CJN.07131009","article-title":"A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease","volume":"5","author":"Moe","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025031300034024900_bib61","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3945\/ajcn.112.040642","article-title":"High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial","volume":"96","author":"Alvarez","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"2025031300034024900_bib62","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1093\/ndt\/gfs138","article-title":"Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D","volume":"27","author":"Marckmann","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2025031300034024900_bib63","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.clnu.2016.05.012","article-title":"Vitamin D3 supplementation, bone health and quality of life in adults with diabetes and chronic kidney disease: results of an open label randomized clinical trial","volume":"36","author":"Mager","year":"2017","journal-title":"Clin Nutr"},{"key":"2025031300034024900_bib64","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1681\/ASN.2017010003","article-title":"A randomized trial of vitamin D supplementation on vascular function in CKD","volume":"28","author":"Kumar","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025031300034024900_bib65","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfx059","article-title":"High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD stages 3-4: results of a 12-week double-blind, randomized, controlled study","volume":"33","author":"Westerberg","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025031300034024900_bib66","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2215\/CJN.00480118","article-title":"Comparative effects of cholecalciferol and calcitriol on circulating markers of CKD mineral bone disorder: a randomized clinical trial","volume":"13","author":"Zelnick","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025031300034024900_bib67","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/ckj\/sfab035","article-title":"Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis","volume":"14","author":"Bover","year":"2021","journal-title":"Clin Kidney J"},{"key":"2025031300034024900_bib68","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1093\/ndt\/gfn367","article-title":"High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients","volume":"23","author":"Tokmak","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2025031300034024900_bib69","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.2215\/CJN.12761211","article-title":"25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis","volume":"7","author":"Armas","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025031300034024900_bib70","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3945\/ajcn.111.025502","article-title":"Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis","volume":"95","author":"Wasse","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"2025031300034024900_bib71","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1053\/j.ajkd.2014.04.020","article-title":"Biochemical parameters after cholecalciferol repletion in hemodialysis: results from the VitaDial randomized trial","volume":"64","author":"Massart","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2025031300034024900_bib72","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.12659\/MSM.892315","article-title":"Long-term cholecalciferol administration in hemodialysis patients: a single-center randomized pilot study","volume":"20","author":"Mieczkowski","year":"2014","journal-title":"Med Sci Monit"},{"key":"2025031300034024900_bib73","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/1744-9987.12279","article-title":"Effects of a single, high oral dose of 25-hydroxycholecalciferol on the mineral metabolism markers in hemodialysis patients","volume":"19","author":"Merino","year":"2015","journal-title":"Ther Apher Dial"},{"key":"2025031300034024900_bib74","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/nu8110708","article-title":"Cholecalciferol additively reduces serum parathyroid hormone and increases vitamin D and cathelicidin levels in paricalcitol-treated secondary hyperparathyroid hemodialysis patients","volume":"8","author":"Zheng","year":"2016","journal-title":"Nutrients"},{"key":"2025031300034024900_bib75","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/nu10020196","article-title":"Cholecalciferol additively reduces serum parathyroid hormone levels in severe secondary hyperparathyroidism treated with calcitriol and cinacalcet among hemodialysis patients","volume":"10","author":"Zheng","year":"2018","journal-title":"Nutrients"},{"key":"2025031300034024900_bib76","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40620-019-00599-x","article-title":"Cholecalciferol supplementation increases FGF23 in peritoneal dialysis patients with hypovitaminosis D: a randomized clinical trial","volume":"32","author":"Ramirez-Sandoval","year":"2019","journal-title":"J Nephrol"},{"key":"2025031300034024900_bib77","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1053\/j.jrn.2021.05.006","article-title":"The effects of cholecalciferol supplementation on FGF23 and \u03b1-klotho in hemodialysis patients with hypovitaminosis D: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Etemadi","year":"2022","journal-title":"J Ren Nutr"},{"key":"2025031300034024900_bib78","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1111\/ajt.16530","article-title":"The effect of cholecalciferol supplementation on allograft function in incident kidney transplant recipients: a randomized controlled study","volume":"21","author":"Doi","year":"2021","journal-title":"Am J Transplant"},{"key":"2025031300034024900_bib79","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/tri.13885","article-title":"Correcting anemia and native vitamin D supplementation in kidney transplant recipients: a multicenter, 2\u00a0\u00d7\u00a02 factorial, open-label, randomized clinical trial","volume":"34","author":"Obi","year":"2021","journal-title":"Transpl Int"},{"key":"2025031300034024900_bib80","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2215\/CJN.06910714","article-title":"Nutritional vitamin D supplementation in dialysis: a randomized trial","volume":"10","author":"Bhan","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025031300034024900_bib81","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/1744-9987.13722","article-title":"Efficacy of high versus conventional dose of ergocalciferol supplementation on serum 25-hydroxyvitamin D and interleukin-6 levels among hemodialysis patients with vitamin D deficiency: a multicenter, randomized, controlled study","volume":"26","author":"Nata","year":"2022","journal-title":"Ther Apher Dial"},{"key":"2025031300034024900_bib82","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1053\/j.ajkd.2011.06.027","article-title":"Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial","volume":"59","author":"Kovesdy","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2025031300034024900_bib83","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3109\/00365513.2012.744464","article-title":"Ergocalciferol treatment and aspects of mineral homeostasis in patients with chronic kidney disease stage 4-5","volume":"73","author":"Gravesen","year":"2013","journal-title":"Scand J Clin Lab Invest"},{"key":"2025031300034024900_bib84","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejphar.2016.07.019","article-title":"Ergocalciferol versus calcitriol for controlling chronic kidney disease mineral bone disorder in stage 3 to 5 CKD: a randomized controlled trial","volume":"789","author":"Zhang","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"2025031300034024900_bib85","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1210\/jc.2012-4287","article-title":"Bioavailability of vitamin D2 and D3 in healthy volunteers, a randomized placebo-controlled trial","volume":"98","author":"Lehmann","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2025031300034024900_bib86","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3945\/jn.112.159764","article-title":"Ergocalciferol from mushrooms or supplements consumed with a standard meal increases 25-hydroxyergocalciferol but decreases 25-hydroxycholecalciferol in the serum of healthy adults","volume":"142","author":"Stephensen","year":"2012","journal-title":"J Nutr"},{"key":"2025031300034024900_bib87","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1017\/S000711451600427X","article-title":"Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial","volume":"116","author":"Wetmore","year":"2016","journal-title":"Br J Nutr"},{"key":"2025031300034024900_bib88","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3945\/ajcn.111.031427","article-title":"Relative effectiveness of oral 25-hydroxyvitamin D3 and vitamin D3 in raising wintertime serum 25-hydroxyvitamin D in older adults","volume":"95","author":"Cashman","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"2025031300034024900_bib89","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/jbmr.4387","article-title":"Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial","volume":"36","author":"P\u00e9rez-Castrill\u00f3n","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2025031300034024900_bib90","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/13543784.2024.2369307","article-title":"Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs","volume":"33","author":"Magagnoli","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"2025031300034024900_bib91","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.03940510","article-title":"Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials","volume":"6","author":"Kandula","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025031300034024900_bib92","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1159\/000369939","article-title":"Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease","volume":"40","author":"Sprague","year":"2014","journal-title":"Am J Nephrol"},{"key":"2025031300034024900_bib93","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000450766","article-title":"Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease","volume":"44","author":"Sprague","year":"2016","journal-title":"Am J Nephrol"},{"key":"2025031300034024900_bib94","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1136\/bmj.282.6280.1919","article-title":"Double-blind trial of oral 1,25-dyhidroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance hemodialysis","volume":"282","author":"Memmos","year":"1981","journal-title":"BMJ (Clin Res Ed)"},{"key":"2025031300034024900_bib95","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000185744","article-title":"Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis","volume":"53","author":"Brandi","year":"1989","journal-title":"Nephron"},{"key":"2025031300034024900_bib96","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000054729","article-title":"Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses","volume":"90","author":"Koshikawa","year":"2002","journal-title":"Nephron"},{"key":"2025031300034024900_bib97","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000186004","article-title":"Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis","volume":"55","author":"Ljunghall","year":"1990","journal-title":"Nephron"},{"key":"2025031300034024900_bib98","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1093\/ndt\/10.12.2228","article-title":"Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial)","volume":"10","author":"Ritz","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"2025031300034024900_bib99","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","article-title":"Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure","volume":"310","author":"Hamdy","year":"1995","journal-title":"BMJ"},{"key":"2025031300034024900_bib100","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3109\/00365599.2012.693131","article-title":"Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: a pilot study","volume":"46","author":"Ivarsen","year":"2012","journal-title":"Scand J Urol Nephrol"},{"key":"2025031300034024900_bib101","first-page":"216","article-title":"Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism","volume":"40","author":"Fischer","year":"1993","journal-title":"Clin Nephrol"},{"key":"2025031300034024900_bib102","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/ki.1994.223","article-title":"Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD","volume":"45","author":"Quarles","year":"1994","journal-title":"Kidney Int"},{"key":"2025031300034024900_bib103","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1681\/ASN.V73488","article-title":"Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients","volume":"7","author":"Levine","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"2025031300034024900_bib104","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000190286","article-title":"\u2018Pulse oral\u2019 versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study","volume":"77","author":"Bacchini","year":"1997","journal-title":"Nephron"},{"key":"2025031300034024900_bib105","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1093\/ndt\/gfn264","article-title":"Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth","volume":"23","author":"Taniguchi","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2025031300034024900_bib106","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1681\/ASN.V561344","article-title":"A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism","volume":"5","author":"Lee","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"2025031300034024900_bib107","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1093\/ndt\/13.5.1234","article-title":"Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial","volume":"13","author":"Moe","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"2025031300034024900_bib108","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1081\/JDI-49538","article-title":"Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study","volume":"27","author":"Gu","year":"2005","journal-title":"Ren Fail"},{"key":"2025031300034024900_bib109","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5414\/CNP65415","article-title":"A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease","volume":"65","author":"Tarrass","year":"2006","journal-title":"Clin Nephrol"},{"key":"2025031300034024900_bib110","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1744-9987.2008.00559.x","article-title":"Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients","volume":"12","author":"Al-Hilali","year":"2008","journal-title":"Ther Apher Dial"},{"key":"2025031300034024900_bib111","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1440-1797.2010.01398.x","article-title":"Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients","volume":"16","author":"Kiattisunthorn","year":"2011","journal-title":"Nephrology"},{"key":"2025031300034024900_bib112","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","article-title":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4","volume":"43","author":"Coburn","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2025031300034024900_bib113","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2025031300034024900_bib114","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000092033","article-title":"A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4","volume":"26","author":"Abboud","year":"2006","journal-title":"Am J Nephrol"},{"issue":"2 Suppl 2","key":"2025031300034024900_bib115","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1053\/ajkd.1998.v32.pm9808143","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2","volume":"32","author":"Llach","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"2025031300034024900_bib116","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"5 Suppl 5","key":"2025031300034024900_bib117","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1053\/ajkd.2001.28112","article-title":"Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study","volume":"38","author":"Martin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2025031300034024900_bib118","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1053\/j.ajkd.2006.04.060","article-title":"Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism","volume":"48","author":"Mitsopoulos","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2025031300034024900_bib119","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000109398","article-title":"Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis","volume":"28","author":"Ross","year":"2008","journal-title":"Am J Nephrol"},{"key":"2025031300034024900_bib120","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/ajt.12227","article-title":"Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial","volume":"13","author":"Amer","year":"2013","journal-title":"Am J Transplant"},{"key":"2025031300034024900_bib121","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1681\/ASN.2013111185","article-title":"Paricalcitol for secondary hyperparathyroidism in renal transplantation","volume":"26","author":"Trillini","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025031300034024900_bib122","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"2025031300034024900_bib123","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1440-1797.2008.01058.x","article-title":"Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism","volume":"14","author":"Abdul Gafor","year":"2009","journal-title":"Nephrology"},{"key":"2025031300034024900_bib124","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/ki.2011.226","article-title":"No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial","volume":"80","author":"Hansen","year":"2011","journal-title":"Kidney Int"},{"key":"2025031300034024900_bib125","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/nep.12029","article-title":"Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism","volume":"18","author":"Ong","year":"2013","journal-title":"Nephrology"},{"key":"2025031300034024900_bib126","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/CJN.10661013","article-title":"A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3\u20134 CKD","volume":"9","author":"Coyne","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025031300034024900_bib127","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10157-013-0844-2","article-title":"Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism","volume":"18","author":"Jamaluddin","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"2025031300034024900_bib128","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/1744-9987.12434","article-title":"Comparison of the pharmacological effects of paricalcitol versus calcitriol on secondary hyperparathyroidism in the dialysis population","volume":"20","author":"Ve\u010deri\u0107-Haler","year":"2016","journal-title":"Ther Apher Dial"},{"key":"2025031300034024900_bib129","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1159\/000089707","article-title":"Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol","volume":"25","author":"Zisman","year":"2005","journal-title":"Am J Nephrol"},{"key":"2025031300034024900_bib130","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4081\/reumatismo.2016.870","article-title":"Guidelines for the diagnosis, prevention and management of osteoporosis","volume":"68","author":"Rossini","year":"2016","journal-title":"Reumatismo"},{"key":"2025031300034024900_bib131","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","article-title":"Vitamin D3 and calcium to prevent hip fractures in elderly women","volume":"327","author":"Chapuy","year":"1992","journal-title":"N Engl J Med"},{"key":"2025031300034024900_bib132","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/metabo12030266","article-title":"Bone fragility in chronic kidney disease stage 3 to 5: the use of vitamin D supplementation","volume":"12","author":"Ure\u00f1a Torres","year":"2022","journal-title":"Metabolites"},{"key":"2025031300034024900_bib133","doi-asserted-by":"publisher","first-page":"sfae227","DOI":"10.1093\/ckj\/sfae227","article-title":"Vitamin D therapy in chronic kidney disease: a critical appraisal of clinical trial evidence","volume":"17","author":"Yeung","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025031300034024900_bib134","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1159\/000188515","article-title":"Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure","volume":"69","author":"Przedlacki","year":"1995","journal-title":"Nephron"},{"key":"2025031300034024900_bib135","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1097\/01.ASN.0000093255.56474.B4","article-title":"Preventing bone loss in renal transplant recipients with vitamin D","volume":"14","author":"El-Agroudy","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2025031300034024900_bib136","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/ndt\/gfg595","article-title":"Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure","volume":"19","author":"Rix","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2025031300034024900_bib137","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1093\/ndt\/gft227","article-title":"Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study","volume":"28","author":"Coyne","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2025031300034024900_bib138","doi-asserted-by":"publisher","first-page":"116581","DOI":"10.1016\/j.bone.2022.116581","article-title":"Impact of treatment with active vitamin D calcitriol on bone turnover markers in people with type 2 diabetes and stage 3 chronic kidney disease","volume":"166","author":"Stathi","year":"2023","journal-title":"Bone"},{"key":"2025031300034024900_bib139","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.nefroe.2021.11.014","article-title":"Hyporesponsiveness or resistance to the action of parathyroid hormone in chronic kidney disease","volume":"41","author":"Bover","year":"2021","journal-title":"Nefrolog\u00eda (Engl Ed)"},{"key":"2025031300034024900_bib140","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1053\/j.ajkd.2023.04.003","article-title":"Vitamin D therapy in adults with CKD: a systematic review and meta-analysis","volume":"82","author":"Yeung","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2025031300034024900_bib141","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/jbmr.4469","article-title":"Cholecalciferol supplementation attenuates bone loss in incident kidney transplant recipients: a prespecified secondary endpoint analysis of a randomized controlled trial","volume":"37","author":"Tsujita","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2025031300034024900_bib142","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ajt.2022.12.007","article-title":"Nonskeletal and skeletal effects of high doses versus low doses of vitamin D","volume":"23","author":"Courbebaisse","year":"2023","journal-title":"Am J Transplant"},{"key":"2025031300034024900_bib143","doi-asserted-by":"publisher","first-page":"790513","DOI":"10.3389\/fmed.2021.790513","article-title":"Non-classical vitamin D actions for renal protection","volume":"8","author":"Dusso","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025031300034024900_bib144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000541138","article-title":"Sustained reduction of elevated intact parathyroid hormone concentrations with extended-release calcifediol slows chronic kidney disease progression in secondary hyperparathyroidism patients","volume":"27","author":"Bishop","year":"2024","journal-title":"Am J Nephrol"},{"key":"2025031300034024900_bib145","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","article-title":"Antiproteinuric effect of oral paricalcitol in chronic kidney disease","volume":"68","author":"Agarwal","year":"2005","journal-title":"Kidney Int"},{"key":"2025031300034024900_bib146","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"2025031300034024900_bib147","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.ajkd.2009.04.036","article-title":"Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial","volume":"54","author":"Fishbane","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2025031300034024900_bib148","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1471-2369-14-163","article-title":"Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial","volume":"14","author":"Larsen","year":"2013","journal-title":"BMC Nephrol"},{"key":"2025031300034024900_bib149","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S2213-8587(17)30359-5","article-title":"Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial","volume":"6","author":"Parvanova","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025031300034024900_bib150","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1093\/ckj\/sfab091","article-title":"Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis","volume":"14","author":"Cozzolino","year":"2021","journal-title":"Clin Kidney J"},{"key":"2025031300034024900_bib151","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/nep.13026","article-title":"Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?","volume":"22","author":"Toussaint","year":"2017","journal-title":"Nephrology"},{"key":"2025031300034024900_bib152","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ypmed.2013.08.026","article-title":"Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis","volume":"57","author":"Yin","year":"2013","journal-title":"Prev Med"},{"key":"2025031300034024900_bib153","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3945\/ajcn.116.140392","article-title":"Serum 25-hydroxyvitamin D and the risk of cardiovascular disease: dose-response meta-analysis of prospective studies","volume":"105","author":"Zhang","year":"2017","journal-title":"Am J Clin Nutr"},{"key":"2025031300034024900_bib154","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1093\/ndt\/gfy016","article-title":"Vitamin D status and mortality risk among patients on dialysis: a systematic review and meta-analysis of observational studies","volume":"33","author":"Zhang","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025031300034024900_bib155","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.kint.2023.07.010","article-title":"Vitamin D supplementation in people with chronic kidney disease","volume":"104","author":"Vervloet","year":"2023","journal-title":"Kidney Int"},{"key":"2025031300034024900_bib156","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1809944","article-title":"Vitamin D supplements and prevention of cancer and cardiovascular disease","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"2025031300034024900_bib157","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S2213-8587(21)00345-4","article-title":"The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality","volume":"10","author":"Neale","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025031300034024900_bib158","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"2025031300034024900_bib159","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1681\/ASN.2013010103","article-title":"Effect of paricalcitol on left ventricular mass and function in CKD\u2014the OPERA trial","volume":"25","author":"Wang","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2025031300034024900_bib160","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1001\/jama.2018.17749","article-title":"Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism receiving maintenance hemodialysis: the J-DAVID randomized clinical trial","volume":"320","author":"Shoji","year":"2018","journal-title":"JAMA"},{"key":"2025031300034024900_bib161","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40620-021-01104-z","article-title":"Calcifediol supplementation in adults on hemodialysis: a randomized controlled trial","volume":"35","author":"Morrone","year":"2022","journal-title":"J Nephrol"},{"key":"2025031300034024900_bib162","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-2369-15-50","article-title":"Cardiovascular effects of cholecalciferol treatment in dialysis patients\u2014a randomized controlled trial","volume":"15","author":"Mose","year":"2014","journal-title":"BMC Nephrol"},{"key":"2025031300034024900_bib163","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1161\/HYPERTENSIONAHA.114.03748","article-title":"Paricalcitol and endothelial function in chronic kidney disease trial","volume":"64","author":"Zoccali","year":"2014","journal-title":"Hypertension"},{"key":"2025031300034024900_bib164","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000441364","article-title":"Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: a randomized trial","volume":"42","author":"Lundwall","year":"2015","journal-title":"Am J Nephrol"},{"key":"2025031300034024900_bib165","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jdiacomp.2015.01.004","article-title":"Effect of paricalcitol on endothelial function and inflammation in type 2 diabetes and chronic kidney disease","volume":"29","author":"Thethi","year":"2015","journal-title":"J Diabetes Complications"},{"key":"2025031300034024900_bib166","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.2215\/CJN.01870217","article-title":"Cholecalciferol, calcitriol, and vascular function in CKD: a randomized, double-blind trial","volume":"12","author":"Kendrick","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025031300034024900_bib167","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.2215\/CJN.10791016","article-title":"Randomized controlled trial for the effect of vitamin D supplementation on vascular stiffness in CKD","volume":"12","author":"Levin","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025031300034024900_bib168","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/bcp.15484","article-title":"Effect of calcitriol treatment on arterial stiffness in people with type 2 diabetes and stage 3 chronic kidney disease","volume":"89","author":"Karalliedde","year":"2023","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/Supplement_1\/i61\/62386176\/sfae417.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/Supplement_1\/i61\/62386176\/sfae417.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:04:01Z","timestamp":1741824241000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/18\/Supplement_1\/i61\/8071682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":168,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2025,3,13]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae417","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]}}}